163 related articles for article (PubMed ID: 21396418)
1. Membrane-active antimicrobial peptides and human placental lysosomal extracts are highly active against mycobacteria.
Jena P; Mishra B; Leippe M; Hasilik A; Griffiths G; Sonawane A
Peptides; 2011 May; 32(5):881-7. PubMed ID: 21396418
[TBL] [Abstract][Full Text] [Related]
2. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.
Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL
Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557
[TBL] [Abstract][Full Text] [Related]
3. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
4. [In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria].
Zerbini E; Andreu D; Tonarelli G; Sequeira MD
Rev Argent Microbiol; 2006; 38(4):221-3. PubMed ID: 17370578
[TBL] [Abstract][Full Text] [Related]
5. The antimicrobial peptide Ci-MAM-A24 is highly active against multidrug-resistant and anaerobic bacteria pathogenic for humans.
Fedders H; Podschun R; Leippe M
Int J Antimicrob Agents; 2010 Sep; 36(3):264-6. PubMed ID: 20627462
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antibacterial and cytotoxic activity of Artemisia nilagirica and Murraya koenigii leaf extracts against mycobacteria and macrophages.
Naik SK; Mohanty S; Padhi A; Pati R; Sonawane A
BMC Complement Altern Med; 2014 Mar; 14():87. PubMed ID: 24597853
[TBL] [Abstract][Full Text] [Related]
9. Designing α-helical peptides with enhanced synergism and selectivity against Mycobacterium smegmatis: Discerning the role of hydrophobicity and helicity.
Khara JS; Lim FK; Wang Y; Ke XY; Voo ZX; Yang YY; Lakshminarayanan R; Ee PLR
Acta Biomater; 2015 Dec; 28():99-108. PubMed ID: 26380930
[TBL] [Abstract][Full Text] [Related]
10. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors.
Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM
Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902
[TBL] [Abstract][Full Text] [Related]
11. [Granulysin: antimicrobial molecule of innate and acquired immunity in human tuberculosis].
Wargnier A; Sasportes M; Lagrange PH
Pathol Biol (Paris); 2005; 53(8-9):516-21. PubMed ID: 16081226
[TBL] [Abstract][Full Text] [Related]
12. Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice.
Yi Z; Fu Y; Yang C; Li J; Luo X; Chen Q; Zeng W; Jiang S; Jiang Y; He Y; Yang J; Liu Y; Li N; Zhu DY
Vaccine; 2007 Jan; 25(4):638-48. PubMed ID: 17000035
[TBL] [Abstract][Full Text] [Related]
13. Conserved structure and function in the granulysin and NK-lysin peptide family.
Linde CM; Grundström S; Nordling E; Refai E; Brennan PJ; Andersson M
Infect Immun; 2005 Oct; 73(10):6332-9. PubMed ID: 16177304
[TBL] [Abstract][Full Text] [Related]
14. Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria.
Pruksakorn P; Arai M; Kotoku N; Vilchèze C; Baughn AD; Moodley P; Jacobs WR; Kobayashi M
Bioorg Med Chem Lett; 2010 Jun; 20(12):3658-63. PubMed ID: 20483615
[TBL] [Abstract][Full Text] [Related]
15. Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages.
Mohanty S; Jena P; Mehta R; Pati R; Banerjee B; Patil S; Sonawane A
Antimicrob Agents Chemother; 2013 Aug; 57(8):3688-98. PubMed ID: 23689720
[TBL] [Abstract][Full Text] [Related]
16. Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-derived peptides.
Purdy GE; Niederweis M; Russell DG
Mol Microbiol; 2009 Sep; 73(5):844-57. PubMed ID: 19682257
[TBL] [Abstract][Full Text] [Related]
17. The potential of human neutrophil peptides in tuberculosis therapy.
Fu LM
Int J Tuberc Lung Dis; 2003 Nov; 7(11):1027-32. PubMed ID: 14598960
[TBL] [Abstract][Full Text] [Related]
18. Short, Synthetic Cationic Peptides Have Antibacterial Activity against Mycobacterium smegmatis by Forming Pores in Membrane and Synergizing with Antibiotics.
Gupta K; Singh S; van Hoek ML
Antibiotics (Basel); 2015 Aug; 4(3):358-78. PubMed ID: 27025629
[TBL] [Abstract][Full Text] [Related]
19. Role of lipids in killing mycobacteria by macrophages: evidence for NF-kappaB-dependent and -independent killing induced by different lipids.
Gutierrez MG; Gonzalez AP; Anes E; Griffiths G
Cell Microbiol; 2009 Mar; 11(3):406-20. PubMed ID: 19016780
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, antimicrobial activity and LPS-interaction properties of SB041, a novel dendrimeric peptide with antimicrobial properties.
Bruschi M; Pirri G; Giuliani A; Nicoletto SF; Baster I; Scorciapino MA; Casu M; Rinaldi AC
Peptides; 2010 Aug; 31(8):1459-67. PubMed ID: 20438783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
